Cadila Healthcare announced that the manufacturing facility of Zydus Hopsira Oncology, a 50:50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is "closed" and states that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from April 5 to 12, 2018.

Shares of the company declined Rs 3, or 0.81%, to trade at Rs 368.50. The total volume of shares traded was 107,976 at the BSE (1.09 p.m., Thursday).